COMMUNIQUÉS West-GlobeNewswire

QuickBurn BHB 2026: What Consumers Should Know About BHB Ketone Supplements Before Buying
27/02/2026
An informational overview of the QuickBurn BHB exogenous ketone supplement — ingredients, BHB salt research, potential side effects, ketosis claims, and what to verify before ordering. Largo, FL, Feb. 26, 2026 (GLOBE [...]
SkinnyRx GLP-1 Weight Loss 2026: Compounded Semaglutide and Tirzepatide Program, Pricing, and FDA Regulatory Status Examined
27/02/2026
Examining SkinnyRx's Compounded GLP-1 Weight Loss Platform for 2026: Semaglutide and Tirzepatide Medication Formats, Subscription Pricing From $199 Per Month, 503A Pharmacy Sourcing, Clinical Research Boundaries, and [...]
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
26/02/2026
Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS II study with higher [...]
MacroGenics to Participate in Upcoming Investor Conferences
26/02/2026
ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced [...]
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
26/02/2026
RADNOR, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities [...]
Anteris Reports 2025 Financial Results and Provides Corporate Update
27/02/2026
MINNEAPOLIS and BRISBANE, Australia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, [...]
Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics
26/02/2026
Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted gross profit and [...]
DeepHealth Achieves CE Mark for TechLive™ and Enables AWS Marketplace Deployment, Advancing Global Expansion of Multimodality Vendor-Agnostic Remote Scanning Solution
26/02/2026
SOMERVILLE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced that TechLive™, its [...]
The Kidney Foundation of Canada highlights need for Canadians to act on kidney health
26/02/2026
Take Action This Kidney Health Month and Ahead of World Kidney Day 2026 MONTREAL, Feb. 26, 2026 (GLOBE NEWSWIRE) -- As Kidney Health Month gets underway, The Kidney Foundation of Canada is calling on Canadians to take [...]
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
26/02/2026
Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”) in October 2025. [...]
Herz P1 Smart Ring in 2026: Features, Pricing, Accuracy Context, and What Consumers Should Verify Before Buying
27/02/2026
Examining the Herz P1 Smart Ring's Consumer Wearable Category for 2026: 24/7 Heart Rate Monitoring, Sleep Tracking, Stress and HRV Analysis, Activity Metrics, Smart Ring Pricing From $49.99 Per Unit, No Subscription [...]
Sprout Health NAD+ Injections — Compounding Status, Pharmacy Sourcing, and What Consumers Should Verify Before Any Telehealth NAD+ Enrollment in 2026
27/02/2026
Compounded NAD+ Telehealth Access, FDA Classification, Pharmacy Sourcing Standards, Prescription Requirements, and Consumer Verification Steps for Evaluating Any NAD+ Injection Program in 2026 Encinitas, CA, Feb. 26, [...]
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/02/2026
– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ (axatilimab-csfr [...]
Ryoncil® Profits Underpinning Substantial Growth Pipeline
27/02/2026
Financial Results and Operational Update for Half-Year Ended December 31, 2025 NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for [...]
UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
26/02/2026
WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent [...]
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financial Results
26/02/2026
Record full year 2025 revenue of $236.3 million increased 15% compared to prior year Operating Cash flow improvement of $22 million in full year 2025 Generated $10 million of free cash flow in the fourth quarter, the [...]
La Fondation canadienne du rein souligne la nécessité pour les Canadiens d'agir pour leur santé rénale
26/02/2026
Agissez pendant ce Mois de la santé rénale et à l'approche de la Journée mondiale du rein 2026 MONTRÉAL, 26 févr. 2026 (GLOBE NEWSWIRE) -- Alors que le Mois de la santé rénale débute, La Fondation canadienne du rein [...]
Tarsus to Participate in Upcoming Investor Conferences
26/02/2026
IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: TD Cowen 46 th Annual [...]
Extendicare Announces 2025 Fourth Quarter and Full Year Results and Dividend Increase
26/02/2026
MARKHAM, Ontario, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three and twelve months ended December 31, 2025. Fourth Quarter 2025 [...]

Pages